Bavarian Nordic expects revenue setback in 2022

Key 2021 figures from Bavarian Nordic’s annual report are in line with projections, but scrape the bottom of previous estimations. 2022 will be a year of investments for the biotech company, which is why an operating deficit is already being forecasted.
Photo: Bavarian Nordic / PR
Photo: Bavarian Nordic / PR
by CHRISTIAN BUNDGAARD, translated by daniel pedersen

Biotech company Bavarian Nordic almost made a comeback in 2021 – but not quite.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading